About
Diagnoptics develops non-invasive devices to measure Advanced Glycation End-products (AGEs) in skin tissue. The AGE Reader provides a quick scan that reveals long-term metabolic stress and biological aging. This measurement supports precise assessment of cardiovascular risk and diabetes complications.
The device uses autofluorescence to detect AGE accumulation in seconds, offering clinicians objective data beyond short-term markers. Professionals can track progress over time and motivate clients toward sustainable health strategies. It enables measured interventions for those at higher risk.
AGEs reflect cumulative damage from glycation and oxidative stress, persisting in tissues for years. Diagnoptics focuses on putting this biomarker at the heart of preventive care through validated technology. Partnerships with universities and hospitals advance its clinical applications.
Longevity Contribution
- Non-invasive skin scan delivers AGE results in 12 seconds without blood draws or discomfort.
- Measures long-term tissue accumulation of AGEs, providing context beyond short-term markers like HbA1c.
- Pioneered the first device for skin autofluorescence to assess AGEs, introduced in 2006.
- Validated for real-time cardiovascular risk prediction in diabetes, renal failure, and other conditions.